Denosumab superior to zoledronic acid in delaying skeletal-related side effects in breast cancer patients
A newly approved drug, denosumab (Xgeva, Amgen), delays skeletal-related side effects for 5 months longer compared to zoledronic acid (Zometa and Reclast, Novartis) in patients with breast cancer and bone metastases, according to phase 3 trial results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas.
Key Points
A newly approved drug, denosumab (Xgeva, Amgen), delays skeletal-related side effects for 5 months longer compared to zoledronic acid (Zometa and Reclast, Novartis) in patients with breast cancer and bone metastases, according to phase 3 trial results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas.
The research, headed by Alison T. Stopeck, MD, associate professor of medicine and director of the Clinical Breast Cancer Program at the University of Arizona's Arizona Cancer Center, randomly assigned 2,046 patients with advanced breast cancer to receive either 120 mg of subcutaneous denosumab or 4 mg of intravenous zoledronic acid every 4 weeks. Results from the study demonstrated that denosumab was better at delaying the time to first on-study, skeletal-related event by 18% and the time to first and subsequent event by 22%. The median time to first on-study, skeletal-related event was 5 months longer for the denosumab group compared to the zoledronic acid group.
Denosumab is more efficacious and better tolerated by patients, Dr Stopeck said.
Overall survival and disease progression was similar for both groups. Rates of side effects were 96.2% for those taking denosumab and 97.4% for those taking zoledronic acid. Osteonecrosis of the jaw occurred in 2.5% of patients taking denosumab and 1.8% of those taking zoledronic acid.
FDA approved denosumab on Nov. 18, 2010, for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
